PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
NanoEnTek is expanding US and European sales of its lab-on-a-chip diagnostic devices, extending a profit recovery after the 2023 loss.
2025 revenue rose 25.2% YoY to KRW 38.1bn, with operating margin improving from 2.0% to 2.9%
Q2 2026 operating profit of KRW 0.69bn marked the highest level in the past five quarters
US subsidiary revenue surpassed domestic sales for the first time in 2024, extending overseas exposure
New product pipeline active in 2026 with the global launch of ADAM-rXBC and EVE-HT A26 and US FDA approval for ADAM II-CD34
Controlling shareholder is the A+Asset Advisors group, a funeral-service and insurance conglomerate unrelated to the core diagnostics business
Founded in 2000 as a Seoul National University campus venture, NanoEnTek holds a core Lab-on-a-Chip platform that fuses micro-electro-mechanical system (MEMS) technology with biotechnology.
Based on this platform, the company develops and manufactures life-science instruments and in-vitro diagnostic (IVD) devices, supplying markets including the United States, Germany, and China.
Its flagship products are the FREND point-of-care diagnostic platform and the ADAM-rWBC automated white blood cell counter, and the ADAM-rWBC series has been adopted as standard blood-quality testing equipment by the American Red Cross.
As of 2021, IVD consumables accounted for roughly 65% of revenue, the largest share, followed by IVD equipment at 8%, life-science consumables at 19%, and life-science equipment at 4%, with the FREND Kit (41.6%) and ADAM-rWBC Kit (23.4%) making up most of product sales.
Most revenue is export-driven from North America and Europe, and in 2024 US subsidiary sales surpassed domestic sales for the first time.
The company acquired 100% of its German subsidiary (MTS Med-Tech Supplies GmbH) in 2024 and brought AAI Healthcare in as a wholly owned subsidiary in October 2025, broadening its business portfolio.
In the competitive landscape, the US IVD market is considered a high-barrier segment dominated by large global manufacturers, where physicians and clinical lab technicians who prioritize reliability are the core user base.
The controlling shareholder is the A+Asset Advisors group, a funeral-service and insurance-based conglomerate that took over management from SK Square in 2023 and further strengthened its control through a 2024 capital increase.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩9B | ₩200M | 2.0% |
| 2025Q3 | ₩8.6B | -₩65,059,131 | −0.8% |
| 2025Q4 | ₩12.6B | ₩900M | 7.2% |
| 2026Q1 | ₩10.5B | ₩100M | 1.4% |
| 2026Q2 | ₩12.5B | ₩700M | 5.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩35.2B | ₩4.4B | ₩4.7B | 12.4% | 8.1% | 9.8% |
| 2023 | ₩26.8B | -₩2.2B | -₩3.7B | −8.3% | −6.9% | 9.3% |
| 2024 | ₩30.5B | ₩600M | ₩3.6B | 2.0% | 4.8% | 6.8% |
| 2025 | ₩38.1B | ₩1.1B | ₩1.6B | 2.9% | 1.7% | 7.7% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
NanoEnTek's annual results have shown pronounced swings.
In 2022, revenue was KRW 35.2bn with an operating profit of KRW 4.4bn (12.4% margin) and net income of KRW 4.7bn, a relatively strong year, but in 2023 revenue fell to KRW 26.8bn and the company swung to an operating loss of KRW 2.2bn (-8.3% margin) and a net loss of KRW 3.7bn.
In 2024, revenue recovered to KRW 30.5bn and operating profit returned to positive territory at KRW 0.6bn (2.0% margin), though net income of KRW 3.6bn reflected a sizable non-operating contribution relative to operating profit.
In 2025, revenue rose to KRW 38.1bn (+25.2% YoY) and operating profit improved to KRW 1.1bn (2.9% margin), yet net income fell to KRW 1.6bn, below 2024, suggesting volatility in non-operating items affected earnings quality.
On a quarterly basis, Q2 2025 posted revenue of KRW 9.0bn and operating profit of KRW 0.18bn but a net loss of KRW 1.1bn, while Q3 2025 saw revenue decline to KRW 8.6bn with an operating loss of KRW 0.07bn yet a net profit of KRW 0.63bn, illustrating a repeated divergence between operating and net results.
Q4 2025 showed a clear seasonal improvement with revenue of KRW 12.6bn, operating profit of KRW 0.91bn, and net income of KRW 1.66bn, and Q1 2026 continued the profitable trend with net income of KRW 1.45bn.
Q2 2026 delivered revenue of KRW 12.5bn, operating profit of KRW 0.69bn, and net income of KRW 2.12bn, the largest operating profit among the past five quarters.
Cumulative attributable net income over the trailing four quarters (Q3 2025 through Q2 2026) reached KRW 5.86bn, which on an annualized basis exceeds the 2024 full-year net income level.
The in-vitro diagnostics (IVD) and point-of-care testing (POCT) markets are generally viewed as a growth industry underpinned by an aging population and rising demand for early detection of infectious diseases.
The US IVD market is a high-value-added but high-barrier segment, dominated by large global manufacturers and centered on physicians and clinical lab technicians who prioritize safety and reliability.
NanoEnTek has obtained US FDA clearance for roughly ten devices and consumables, and the adoption of its ADAM-rWBC series as standard equipment by the American Red Cross underpins its technical credibility.
Domestically, companies such as Access Bio, Humasis, Boditech Med, LabGenomics, and SD Biosensor's peer SuGenTech have been cited as comparable players in similar business segments. NanoEnTek's overseas revenue share has continued to expand, with distribution strengthening centered on the United States and Germany.
The European market is known to carry high entry barriers due to demanding quality requirements spanning installation qualification (IQ), operational qualification (OQ), performance qualification (PQ), and process management (PM), in addition to logistics.
The company has stated it will focus on expanding global sales centered on the United States and Germany in 2026.
Having already secured a leading position in testosterone diagnostics in the US, it has completed development of a female hormone diagnostic product to pursue market share gains, and the company has said it expects related diagnostic demand to increase as US regulatory easing is projected to expand the female hormone therapy market.
The new product pipeline has also been rolling out sequentially: in February 2026 the ADAM-rXBC blood product analyzer was launched globally, and in April the EVE-HT A26 mass cell analysis automation robot, developed at the request of major global pharmaceutical companies, was launched globally.
In July, the ADAM II-CD34 automated hematopoietic stem cell counter (frozen HPC-A) received US FDA approval, further expanding the product lineup. How much these new products translate into actual revenue will be a key point to watch in coming results.
In addition, since AAI Healthcare was brought in as a wholly owned subsidiary in October 2025, the business synergy effects from that subsidiary also warrant monitoring.
Given the business structure's high reliance on overseas revenue, the impact of currency fluctuations and regulatory approval timelines across different countries on results also needs continued observation.
NanoEnTek has moved from a net loss in 2023 to profitability in 2024 and 2025, showing a gradual recovery in earnings, though the absolute scale of profit has not yet returned to 2022 levels.
Amid this earnings recovery, the stock has tended to trade at a premium to net asset value, with its price-to-book ratio sitting above 1x. The company has not paid a cash dividend in recent fiscal years, making shareholder returns through dividends relatively limited for now.
While the direction of earnings is improving, the swings between operating profit and net income across quarters mean that valuation interpretation should also account for the influence of one-off non-operating items.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
US subsidiary revenue surpassed domestic sales for the first time in 2024, and the FREND product line grew sharply year over year.
European sales are also reported to have expanded rapidly following the acquisition of the German subsidiary, with expansion proceeding simultaneously across the North American and European axes. This is one factor behind the 25.2% year-over-year revenue growth in 2025.
Since early 2026, the product lineup has continued to expand with the global launches of ADAM-rXBC and EVE-HT A26 and US FDA approval for ADAM II-CD34. Notably, EVE-HT A26 was developed at the request of a major global pharmaceutical company, suggesting a relationship with a large customer. Completion of the female hormone diagnostic product also broadens the diagnostic portfolio in the US market.
Operating margin has gradually improved from -8.3% in 2023 to 2.0% in 2024 and 2.9% in 2025, with the operating profit share of revenue rising further in Q2 2026. This can be interpreted as a fixed-cost leverage effect emerging alongside revenue growth. If new products begin contributing meaningfully to sales, this improving trend could continue.
There have been repeated instances where operating profit and net income moved in opposite directions on a quarterly basis. Q2 2025 posted an operating profit but a net loss, while Q3 2025 recorded an operating loss but net income, suggesting a significant influence from non-operating items. This volatility can reduce the predictability of results.
The controlling shareholder, the A+Asset Advisors group, is primarily a funeral-service and insurance company with no clear direct synergy with the diagnostics business.
Since taking over management from SK Square in 2023, ownership has changed frequently, including a further strengthening of control via a 2024 capital increase. The influence of the group's overall strategic direction on company management warrants continued observation.
Operating profit in 2025 stood at roughly KRW 1.1bn, still substantially below the KRW 4.4bn recorded in 2022. Although revenue has grown, the absolute scale of profit recovery has not yet returned to its prior peak level. If new product revenue contributions are delayed, the pace of profit recovery could slow.
Since a large portion of revenue is generated overseas in an export-oriented structure across North America and Europe, fluctuations in the dollar and euro against the won can directly affect revenue and margins.
As the operational weight of overseas subsidiaries (US, Germany) grows, currency exposure expands correspondingly.
In-vitro diagnostic devices require approval from regulatory bodies such as the US FDA and European certification authorities, and delays or changes in approval conditions can affect new product launch timelines.
The European market is known to carry high entry barriers due to demanding quality requirements including installation, operational, and performance qualification.
Given that the controlling shareholder group is based in funeral services and insurance with no direct connection to diagnostics, future capital allocation decisions and inter-affiliate transactions warrant observation.
Since the ownership structure has continued to shift through capital increases and open-market purchases, further disclosures on ownership changes should also be monitored.
Q3 2026 quarterly report disclosure (provisional results) - a point to check whether new product revenue contribution and the operating margin improvement trend continue.
Need to confirm the actual revenue contribution from ADAM-rXBC, EVE-HT A26, and ADAM II-CD34, which were launched or approved in February, April, and July respectively.
A point to track is whether the female hormone diagnostic product secures regulatory approval and launches in the US, along with progress in expanding related market share.
Ongoing monitoring of disclosures regarding changes in the shareholding ratio of the controlling shareholder, the A+Asset Advisors group, and its related parties, is warranted.
NanoEnTek is in a recovery phase, having emerged from a net loss in 2023 and showing revenue growth alongside operating margin improvement in 2024 and 2025. 2025 revenue rose 25.2% year over year and operating margin increased from 2.0% to 2.9%, with this trend continuing into the first half of 2026.
However, qualitative volatility in earnings persists, as evidenced by the divergent direction of operating profit and net income across quarters, and the absolute scale of profit has not yet recovered to 2022 levels.
Expanding overseas revenue centered on the US and Europe, along with the active 2026 new product pipeline, stand out as positive factors, but the funeral-service and insurance-based ownership structure and uncertainties related to currency and regulatory approvals are variables that also warrant attention.
The upcoming Q3 results and the actual revenue contribution from new products are likely to serve as important reference points for assessing the trajectory going forward.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.